## lipid nanoparticles

	NCT Number	Title	Authors	Description	Identifier	Dates
1	pubmed:36085501	Lipid nanoparticle drug delivery		No abstract	pmid:36085501 doi:10.1038/s41587-022-01462-4	Sat, 10 Sep 2022 06:00:00 -0400
2	pubmed:36090974	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects	Tao Huang Lushan Peng Yingying Han Dan Wang Xiaoyun He Junpu Wang Chunlin Ou	Messenger RNA (mRNA) vaccines constitute an emerging therapeutic method with the advantages of high safety and efficiency as well as easy synthesis; thus, they have been widely used in various human diseases, especially in malignant cancers. However, the mRNA vaccine technology has some limitations, such as instability and low transitive efficiency in vivo, which greatly restrict its application. The development of nanotechnology in the biomedical field offers new strategies and prospects for	pmid:36090974 pmc:PMC9458914 doi:10.3389/fimmu.2022.922301	Mon, 12 Sep 2022 06:00:00 -0400
3	pubmed:36098251	Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia	Tetiana Korzun Abraham S Moses Jeonghwan Kim Siddharth Patel Canan Schumann Peter R Levasseur Parham Diba Brennan Olson Katia Graziella De Oliveira Rebola Mason Norgard Youngrong Park Ananiya A Demessie Yulia Eygeris Vladislav Grigoriev Subisha Sundaram Tanja Pejovic Jonathan R Brody Olena R Taratula Xinxia Zhu Gaurav Sahay Daniel L Marks Oleh Taratula	This study presents the first messenger RNA (mRNA) therapy for metastatic ovarian cancer and cachexia-induced muscle wasting based on lipid nanoparticles that deliver follistatin (FST) mRNA predominantly to cancer clusters following intraperitoneal administration. The secreted FST protein, endogenously synthesized from delivered mRNA, efficiently reduces elevated activin A levels associated with aggressive ovarian cancer and associated cachexia. By altering the cancer cell phenotype, mRNA	pmid:36098251 doi:10.1002/smll.202204436	Tue, 13 Sep 2022 06:00:00 -0400
4	pubmed:36100737	Quality by Design Based Development and Validation of HPLC Method for Simultaneous Estimation of Pregabalin and Piperine in Dual Drug Loaded Liposomes	Isha Gupta Syeda Nashvia Adin Mohd Aqil Mohd Mujeeb Yasmin Sultana	The current research work limns the development of a rapid HPLC method for concurrent detection of pregabalin (PRG) and piperine (PIP) in dual drug-loaded nanoformulations. The primary goal was to recognize the chromatographic conditions wherein propitious segregation of the integrants with quality peaks can be attained. An attempt to expound the target analytical profile (TAP) was made to accomplish this goal, and critical method attributes (CMA) viz. % acetonitrile content, injection volume	pmid:36100737 doi:10.1002/bmc.5510	Tue, 13 Sep 2022 06:00:00 -0400